$HIT

Health In Tech, Inc.

CIK:0002019505|SEC Filings

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenues
Total revenues	$ 8,056,620	$ 9,313,849	$ 16,828,266	$ 17,328,833
Cost of revenues	4,134,127	3,003,979	8,396,374	5,663,564
Gross profit	3,922,493	6,309,870	8,431,892	11,665,269
Operating expenses
Sales and marketing expenses	2,215,889	1,226,738	4,507,490	2,316,993
General and administrative expenses	4,269,094	3,775,453	7,724,652	7,022,218
Research and development expenses	875,811	582,609	1,796,206	1,120,330
Total operating expenses	7,360,794	5,584,800	14,028,348	10,459,541
Other income (expense):
Interest income	69,568	108,198	137,039	193,564
Other income	100,000		122,334	118,399
Other expense	(52,341)		(52,341)
Total other income, net	117,227	108,198	207,032	311,963
(Loss) income before income tax expense	(3,321,074)	833,268	(5,389,424)	1,517,691
Income tax benefit (expense)	809,888	(202,637)	1,289,957	(388,468)
Net (loss) income	(2,511,186)	630,631	(4,099,467)	1,129,223
Net loss attributable to noncontrolling interests	(162)		(162)
Net (loss) income attributable to common stockholders	$ (2,511,024)	$ 630,631	$ (4,099,305)	$ 1,129,223
Net (loss) income per share:
Basic (in Dollars per share)	$ (0.04)	$ 0.01	$ (0.07)	$ 0.02
Diluted (in Dollars per share)	$ (0.04)	$ 0.01	$ (0.07)	$ 0.02
Weighted average common shares outstanding:
Basic (in Shares)	62,829,725	55,382,395	60,106,502	55,003,233
Diluted (in Shares)	62,829,725	55,632,357	60,106,502	57,004,070
Revenues from underwriting modeling (ICE)
Revenues
Total revenues	$ 1,272,647	$ 2,090,576	$ 2,741,461	$ 4,442,560
Revenues from fees (SMR)
Revenues
Total revenues	$ 6,783,973	$ 7,223,273	$ 14,086,805	$ 12,886,273

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (4,099,467)	$ 1,129,223
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Bad debt (recovery) expense	(2,954)	5,990
Amortization expense	723,787	271,966
Provision for refund liability	108,402	955,743
Provision for credit losses on other receivables	739,773
Deferred tax benefit	(1,298,111)	(66,547)
Interest income	(31,998)	(31,998)
Stock-based compensation expense	1,325,882	1,201,134
Changes in operating assets and liabilities:
Accounts receivable	(7,787,065)	359,982
Other receivables	(71,444)	(3,354,582)
Prepaid expenses and other assets	798,039	(561,907)
Operating lease right-of-use assets and liabilities, net	(1,211)	37
Accounts payable and accrued expenses	4,364,800	2,269,897
Income taxes payable		(170,309)
Other current liabilities	(1,000,000)
Net cash (used in) provided by operating activities	(6,231,567)	2,008,629
CASH FLOWS FROM INVESTING ACTIVITIES:
Development of software	(959,123)	(1,613,372)
Net cash used in investing activities	(959,123)	(1,613,372)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock in connection with private investment in public equity financing, net of placement agent fees and escrow agent fees	6,381,000
Payments of deferred offering costs	(243,608)	(106,339)
Contributions from noncontrolling interests	71,428
Taxes paid related to net share settlement of equity awards	(173,071)
Net cash provided by (used in) financing activities	6,035,749	(106,339)
(Decrease) increase in cash and cash equivalents	(1,154,941)	288,918
Cash and cash equivalents, beginning of period	7,669,754	7,849,248
Cash and cash equivalents, end of period	6,514,813	8,138,166
Supplemental disclosures of cash flow information:
Cash paid for interest
Cash paid for income taxes	10,035	625,323
Summary of noncash investing and financing activities:
Accrued deferred offering costs included in accounts payable and accrued expenses	215,911
Accrued development of software included in accounts payable and accrued expenses	430,386	265,243
Reclassification of deferred offering costs to additional paid-in capital upon private investment in public equity financing	527,910
Stock-based compensation capitalized for software development	$ 19,454

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash and cash equivalents	$ 6,514,813	$ 7,669,754
Accounts receivable, net	8,546,307	756,288
Loans receivable, net	847,993	815,995
Other receivables, net	3,392,082	3,467,814
Deferred offering costs	102,586	170,977
Prepaid expenses and other current assets	2,380,284	3,280,148
Total current assets	21,784,065	16,160,976
Non-current assets
Software	7,197,718	6,530,894
Operating lease – right of use assets	104,277	139,940
Long-term prepaid expenses	8,184	258,151
Deferred tax assets, net	540,436
Total non-current assets	7,850,615	6,928,985
Total assets	29,634,680	23,089,961
Current liabilities
Accounts payable and accrued expenses	9,907,370	4,188,811
Operating lease liabilities – current	81,225	76,195
Other current liabilities		891,598
Total current liabilities	9,988,595	5,156,604
Non-current liabilities
Deferred tax liabilities		757,675
Operating lease liabilities – non-current	21,713	63,617
Total non-current liabilities	21,713	821,292
Total liabilities	10,010,308	5,977,896
Commitments and contingencies (Note 5)
Stockholders’ equity
Additional paid-in capital	18,365,473	11,834,121
Retained earnings	1,120,933	5,220,238
Noncontrolling interests	72,408
Total stockholders’ equity	19,624,372	17,112,065
Total liabilities and stockholders’ equity	29,634,680	23,089,961
Class A Common Stock
Stockholders’ equity
Common stock, value	53,858	46,006
Class B Common Stock
Stockholders’ equity
Common stock, value	$ 11,700	$ 11,700